Novo Nordisk A/S’s (NVO) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. reiterated their neutral rating on shares of Novo Nordisk A/S (NYSE:NVO) in a report published on Tuesday morning, MarketBeat.com reports.

Other analysts have also issued research reports about the stock. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Nordea Equity Research lowered Novo Nordisk A/S to a “hold” rating in a research note on Tuesday. The Goldman Sachs Group restated a “buy” rating on shares of Novo Nordisk A/S in a research note on Thursday, January 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Six research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $56.07.

Novo Nordisk A/S Trading Down 1.4%

Shares of NYSE:NVO opened at $37.62 on Tuesday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52-week low of $37.31 and a 52-week high of $91.90. The stock has a market cap of $167.97 billion, a price-to-earnings ratio of 10.84 and a beta of 0.67. The business has a 50-day moving average price of $52.96 and a 200-day moving average price of $52.93.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The firm also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is currently 23.63%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. True Wealth Design LLC increased its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company’s stock worth $25,000 after acquiring an additional 300 shares in the last quarter. Guerra Advisors Inc purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth about $25,000. Godfrey Financial Associates Inc. acquired a new position in shares of Novo Nordisk A/S during the 4th quarter worth about $25,000. WealthCollab LLC raised its position in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. Finally, American National Bank & Trust purchased a new position in Novo Nordisk A/S in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Positive Phase‑2 China results for a triple‑agonist (UBT251) that produced ~20% body‑weight loss, bolstering Novo’s obesity pipeline and collaboration footprint in Greater China. Novo Nordisk’s China Obesity Drug Cuts Nearly One-Fifth Of Body Weight
• Positive Sentiment: Novo signed a strategic deal with Vivtex to develop next‑generation oral obesity/diabetes medicines (deal valued up to ~$2.1bn), which could extend market reach beyond injectables if the oral delivery works at scale. Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs
• Neutral Sentiment: Short interest fell meaningfully in February (roughly a 15% drop), reducing one source of selling pressure and lowering the days‑to‑cover — a technical datapoint worth monitoring for volatility changes.
• Negative Sentiment: Multiple analyst downgrades and coverage cuts have pressured the stock, with recent notes and headlines pointing to reduced ratings and target cuts amid pipeline and competitive concerns. Novo Nordisk A/S (NYSE:NVO) Stock Rating Lowered by Kepler Capital Markets
• Negative Sentiment: Shareholder litigation inquiries and class‑action investigations have been announced (Pomerantz, Schall Law Firm), creating legal overhang and potential costs/distraction for management. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
• Negative Sentiment: Pricing pressure and a reported halving of Wegovy prices have heightened margin and competitive concerns, feeding the narrative of a structural challenge in the obesity franchise. Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.